Article Text

The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study
  1. Sigrun Alba Johannesdottir Schmidt1,
  2. Martin Berg Johansen1,
  3. Morten Olsen1,
  4. Xiao Xu2,
  5. Joseph M Parker3,
  6. Nestor A Molfino4,
  7. Timothy L Lash1,5,
  8. Henrik Toft Sørensen1,
  9. Christian Fynbo Christiansen1
  1. 1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, Denmark
  2. 2AstraZeneca LP, Gaithersburg, Maryland, USA
  3. 3Medimmune LLC, Gaithersburg, Maryland, USA
  4. 4KaloBios Pharmaceuticals, Inc, South San Francisco, California, USA
  5. 5Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
  1. Correspondence to Dr Sigrun Alba Johannesdottir Schmidt; saj{at}clin.au.dk

Abstract

Objective To examine the association between exacerbation frequency and mortality following an acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

Design Cohort study using medical databases.

Setting Northern Denmark.

Participants On 1 January 2005, we identified all patients with prevalent hospital-diagnosed chronic obstructive pulmonary disease (COPD) who had at least one AECOPD during 1 January 2005 to 31 December 2009. We followed patients from the first AECOPD during this period until death, emigration or 31 December 2009, whichever came first. We flagged all AECOPD events during follow-up and characterised each by the exacerbation frequency (0, 1, 2 or 3+) in the prior 12-month period.

Main outcomes and measures Using Cox regression, we computed 0–30-day and 31–365-day age-adjusted, sex-adjusted, and comorbidity-adjusted mortality rate ratios (MRRs) with 95% CIs entering exacerbation frequency as a time-varying exposure.

Results We identified 16 647 eligible patients with prevalent COPD, of whom 6664 (40%) developed an AECOPD and were thus included in the study cohort. The 0–30-day MRRs were 0.97 (95% CI 0.80 to 1.18), 0.90 (95% CI 0.70 to 1.15) and 1.03 (95% CI 0.81 to 1.32) among patients with AECOPD with 1, 2 and 3+ AECOPDs versus no AECOPD within the past 12 months, respectively. The corresponding MRRs were 1.47 (95% CI 1.30 to 1.66), 1.89 (95% CI 1.59 to 2.25) and 1.59 (95% CI 1.23 to 2.05) for days 31–365.

Conclusion Among patients with AECOPD, one or more exacerbations in the previous year were not associated with 30-day mortality but were associated with an increased 31–365-day mortality.

  • Cohort study
  • Registry study
  • Severe exacerbations
  • Time-varying exposure

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement: